Genetic Signatures (GSS) Q1 2026 TU earnings summary

Executive summary

• Achieved quarterly sales of $5.4 million, up 20% from the previous quarter and 15% year-over-year, marking the highest revenue since COVID.

• Revenue growth was driven by all regions: Australia secured new business, EMEA saw a 52% increase in GI testing, and the US received its first commercial order.

• Signed two new US contracts, including one with a major integrated healthcare system, and delivered the first shipment of test kits.

• Strengthened leadership with the appointment of a new CTO and expanded the technology team.

Financial highlights

• Receipts from customers totaled $5.6 million for the quarter.

• Net operating cash outflow was $2.1 million; net investing cash outflow was $0.4 million.

• Cash and term deposit balance at quarter-end was $28.2 million.

• Payments to directors and CEO totaled $0.3 million, included in staff costs.

Outlook and guidance

• Focus remains on strengthening the Australian base and accelerating expansion in the US and UK.

• Solid cash position supports continued investment in commercial and R&D initiatives.